Bildkälla: Stockfoto

CLS Q1’22: Our Comments - Redeye

Redeye provides its comments on CLS’ Q1’22 report. With ongoing discussions with potential new commercial partners in the urology segment, three new clinical studies initiated as well as a pending 510(k) approval for the second generation of TRANBERG Thermal Therapy System with Thermoguide Workstation, the company has an interesting period ahead.

Redeye provides its comments on CLS’ Q1’22 report. With ongoing discussions with potential new commercial partners in the urology segment, three new clinical studies initiated as well as a pending 510(k) approval for the second generation of TRANBERG Thermal Therapy System with Thermoguide Workstation, the company has an interesting period ahead.
Börsvärldens nyhetsbrev
ANNONSER